WallStSmart
SOPH

Sophia Genetics SA

NASDAQ: SOPH · HEALTHCARE · HEALTH INFORMATION SERVICES

$4.63
+0.81% today

Updated 2026-06-05

Market cap
$387.67M
P/E ratio
P/S ratio
4.63x
EPS (TTM)
$-1.18
Dividend yield
52W range
$3 – $6
Volume
0.1M

Sophia Genetics SA (SOPH) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2019202020212022202320242025
Revenue$25.36M$28.40M$40.45M$47.56M$62.37M$65.17M$77.27M
Revenue growth (YoY)+12.0%+42.4%+17.6%+31.1%+4.5%+18.6%
Cost of revenue$7.53M$10.71M$15.23M$16.31M$19.46M$21.24M$29.46M
Gross profit$17.83M$17.69M$25.22M$31.25M$42.91M$43.94M$47.81M
Gross margin70.3%62.3%62.4%65.7%68.8%67.4%61.9%
R&D$15.02M$18.59M$26.58M$35.37M$36.97M$34.37M$33.57M
SG&A$15.67M$18.96M$41.51M$55.82M$53.30M$46.95M$86.07M
Operating income$-32.29M$-37.39M$-71.49M$-87.82M$-74.83M$-66.57M$-70.92M
Operating margin-127.3%-131.6%-176.7%-184.7%-120.0%-102.1%-91.8%
EBITDA$-30.74M$-37.99M$-69.24M$-81.38M$-69.57M$-50.76M$-61.40M
EBITDA margin-121.2%-133.8%-171.2%-171.1%-111.5%-77.9%-79.5%
EBIT$-32.65M$-40.38M$-72.85M$-86.95M$-77.91M$-59.36M$-70.92M
Interest expense$976000.00$840000.00$658000.00$639000.00$588000.00$1.91M$4.55M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-33.79M$-39.34M$-73.67M$-87.45M$-78.98M$-62.49M$-79.00M
Net income growth (YoY)-16.4%-87.3%-18.7%+9.7%+20.9%-26.4%
Profit margin-133.2%-138.5%-182.1%-183.9%-126.6%-95.9%-102.2%

Frequently asked questions

What is Sophia Genetics SA's revenue?

Sophia Genetics SA's trailing twelve-month revenue is $81.18M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is SOPH?

In its most recent fiscal year, SOPH ran a gross margin of 61.88%, an operating margin of -91.79%, and a net margin of -102.24%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does SOPH generate?

SOPH produced $-38.59M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is SOPH's balance sheet healthy?

SOPH holds $70.29M in cash and equivalents against $47.73M in long-term debt, on $47.15M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.